Published within
|«
«
|
1
|
2
|
3
|
4
|
»
»|
| Type |
Product title / description
|
Pub
|
Price |
CommentWire
|
Wyeth's performance in 2002 was negatively affected by its heavy reliance on its Women's Health franchise. With the anticipated launch of Flumist, it is expected that 2003 will mark the beginning of Wyeth's transition from a reliance on HRT treatments to a more diversified portfolio.<BR />
Published By Datamonitor
|
05 Jun 2003 |
|
CommentWire
|
The continuing rollout of J&J's Evra marks an important development in the $4 billion hormonal contraception market. Oral pills have dominated the market for more than 40 years, but with competitive pricing, convenient dosing and the support of family planning organizations, the consumer friendly patch could shake everything up.
Published By Datamonitor
|
18 Jun 2003 |
|
CommentWire
|
The UK Million Women study has confirmed that current or recent users of all types of HRT face an increased risk of developing breast cancer. The HRT market is already depressed after the findings of last year's Women's Health Initiative (WHI) in the US. This study is likely to spell the end of long-term HRT use.<BR />
Published By Datamonitor
|
08 Aug 2003 |
|
CommentWire
|
Last week saw two significant events in the European osteoporosis market: a proposed British launch date for Lilly's [LLY] Forsteo was revealed, and Roche [ROCZ.S]/GSK's [GSK.L] Boniva was recommended for approval. Both products would add much needed weight to the battery of osteoporosis drugs currently available in Europe, but challenges remain in terms of price and physician awareness.
Published By Datamonitor
|
28 Oct 2003 |
|
CommentWire
|
Lilly ICOS' Cialis joins Bayer [BAY.F]/GSK's [GSK.L] Levitra and Pfizer's [PFZ.L] Viagra in the fight against erectile dysfunction after receiving FDA approval earlier this month. Although Cialis offers several advantages over rival products, Lilly ICOS will have to go head-to-head with the leading players. This makes the adoption of effective promotional campaigns vital for success.
Published By Datamonitor
|
27 Nov 2003 |
|
CommentWire
|
Ferring's next generation of antidiuretics to treat urinary incontinence could make use of pioneering research by Nobel Laureate Professor Agre. The company's close relationship with academia and its own long history of research in the urinary incontinence field should strengthen its position as a leading urology player.
Published By Datamonitor
|
01 Mar 2004 |
|
CommentWire
|
The green light for Boniva sees it join Merck & Co's [MRK] Fosamax and Aventis's [SNY] Actonel as the newest member of the bisphosphonate family - a class of drugs that treat osteoporosis by increasing bone mineral density. Adherence to bisphosphonate regimens can be difficult for many patients, but Boniva's monthly formulation offers a major advance in overcoming this issue.
Published By Datamonitor
|
30 Mar 2005 |
|
CommentWire
|
More than two years since its initial approval, Novartis' COX-2 anti-inflammatory Prexige has been launched in the UK. Backed by leading British research and positive data from a number of recent clinical trials, the drug should experience a good uptake in the UK, which will no doubt be reflected across Europe when it hits continental markets this year.
Published By Datamonitor
|
20 Jan 2006 |
|
CommentWire
|
New phase III data have confirmed previous results showing Vernalis and Endo's Frova to be an effective preventative treatment for menstrual migraine. This should pave the way for the migraine drug's approval in this additional indication. Anticipated in 2007, this approval is then expected to transform Frova's sales significantly.
Published By Datamonitor
|
08 May 2006 |
|
CommentWire
|
Sanofi-Aventis and Procter & Gamble's Actonel has been given the green light for the treatment of male osteoporosis in the EU and US. This new indication for Actonel is good news for both companies, but the drug will still have to compete with Merck & Co's Fosamax, which is by far the biggest-selling therapy in the osteoporosis market.
Published By Datamonitor
|
18 Aug 2006 |
|
|«
«
|
1
|
2
|
3
|
4
|
»
»|
No help is available.
Reports and briefs contain analyst driven analysis and opinion covering a specific market or issue.
Business Insight reports are an objective source of data, analysis and market insight
Insight for technology vendors into customer trends and pain points from key business decision makers.
Butler Group's thought leadership, opinion, with end user case studies and product profiles for key vendors.
Butler Group's vendor ranking and assessment model groups vendors into Outperform, Perform, and Under-perform categories.
Butler Group's thought leadership, opinion, and best practice with technology audits, product comparisons and rankings.
Opinion and market commentary from Datamonitor's industry experts.
Company profiles deliver detailed insight into how companies are organized and function with SWOT analysis.
Company reports provide detailed company evaluations.
Opinion and market commentary from Datamonitor's industry experts.
Company reports provide detailed company evaluations.
Opinion and market commentary from Datamonitor's industry experts.
Opinion and market commentary from Datamonitor's industry experts.
Track industry events, markets, products, customers, prospects, competitors and partners
Country profiles presenting easy-to-digest summaries and standardized data.
Databooks use charts and tables to provide a data-centric view of a particular market or category
Opinion and market commentary from Datamonitor's industry experts.
Comprehensive category data, including market value, volume, segmentation and share, with analysis.
Industry profiles provide standardized market data (including size & segmentation) and competitive analysis.
Market sizing and forecast data for a market or sector delivered in spreadsheet format.
Track industry events, markets, products, customers, prospects, competitors and partners
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Reports and briefs contain analyst driven analysis and opinion covering a specific market or issue.
Opinion and market commentary from Datamonitor's industry experts.
Insight for technology vendors into customer trends and pain points from key business decision makers.
Business information covering a specific market or issue.